[This Week's IPO] Demand Forecast and Subscription Schedule for the Fourth Week of March

by Jang Hyowon

Published 24 Mar.2024 08:00(KST)

In the fourth week of this month (March), IMBDX will conduct a general subscription.

◆IMBDX= The final public offering price was set at 13,000 KRW. In the institutional investor demand forecast, 100% of institutions (including those without price indication) proposed prices above the upper limit of the offering price band of 9,900 KRW, and the final competition rate recorded was 865.73 to 1. The general subscription will be held for two days from the 25th to the 26th, and the scheduled listing date is April 3. The underwriter is Mirae Asset Securities.

Founded in 2018, IMBDX is the first company in Korea to successfully apply a cancer precision medicine and early diagnosis platform clinically. The company holds a unique domestic liquid biopsy portfolio specialized in the entire cycle of cancer treatment, including ▲ AlphaLiquid?100 and AlphaLiquid?HRR, profiling products for precision diagnosis and treatment of advanced cancer ▲ CancerDetect, which detects minimal residual cancer after surgery to monitor recurrence ▲ CancerFind, an early cancer diagnosis screening product that has expanded the market to healthy individuals.